Answers are grounded in this paper and cite their sources.
India’s healthcare landscape is uniquely burdened by the dual challenges of rising non-communicable diseases and persistent infectious diseases, compounded by profound genetic and environmental diversity. While pharmacogenomics and therapeutic drug monitoring (TDM) have made strides in tailoring drug therapy, they remain insufficient to fully capture the dynamic, non-genetic contributors to drug response variability. This review explores the emerging role of epigenetics—heritable yet reversible modifications that regulate gene expression without altering the DNA sequence—as a critical, underutilized layer in India’s journey toward precision medicine. We detail the mechanisms of DNA methylation, histone modifications, and non-coding RNAs in regulating drug metabolism and transport and highlight their relevance in major disease domains prevalent in India, including cancer, diabetes, tuberculosis, and hypertension. Special attention is given to epigenetic alterations induced by diet, malnutrition, pollution, and psychosocial stress, which are particularly relevant in the Indian socio-environmental context. We also examine the challenges of integrating epigenetic data into clinical practice—cost, infrastructure, dynamic variability—and outline a strategic roadmap involving public-private consortia, biomarker validation, indigenous diagnostics, and clinician training. By transcending static pharmacogenomic models, epigenetically informed TDM has the potential to transform India’s reactive, one-size-fits-all prescribing paradigm into a proactive, personalized therapeutic approach.
No takes yet. Share an insight, caveat, or question.
Samuel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: